Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00716989
Other study ID # 2006.457
Secondary ID
Status Terminated
Phase N/A
First received July 15, 2008
Last updated December 22, 2010
Start date November 2008
Est. completion date September 2009

Study information

Verified date December 2010
Source Hospices Civils de Lyon
Contact n/a
Is FDA regulated No
Health authority France: Direction Générale de la Santé
Study type Interventional

Clinical Trial Summary

The goal of the vaccination is to induce humoral (antibody) and intracellular (T lymphocyte) responses. Various data show that intradermal vaccination is more efficient than intramuscular vaccination: the humoral response is statistically better after intradermic vaccination, compared to intramuscular vaccination, even in target populations such as older subjects or immunosuppressed patients


Description:

Realisation of 2 groups of healthy subjects with 2 intradermal injection of 50 µl of tuberculin + 2 intradermal injection of 50 µl of physiological serum. 5 biopsy performed on 2 Tuberculin injection site, 2 physiological serum site and 1 on healthy skin site :

- Group A : healthy young subjects(18 to 40 years old) : 18 subjects

- Sub-group A1 (biopsy 30 minutes after injection) : 6 subjects

- Sub-group A2 (biopsy 4 hours after injection) : 6 subjects

- Sub-group A3 (biopsy 72 hours after injection) : 6 subjects

- Group B : healthy old subjects(60 to 75 years old) : 18 subjects

- Sub-group B1 (biopsy 30 minutes after injection) : 6 subjects

- Sub-group B2 (biopsy 4 hours after injection) : 6 subjects

- Sub-group B3 (biopsy 72 hours after injection) : 6 subjects

Determination of the best time (30 minutes, 4 hours or 72 hours)for intradermal vaccination caracteristics after group A and B data analysis. From these results, last group of immunosuppressed patients performed:Group C with 6 immunosuppressed patients (18 to 60 years old)


Recruitment information / eligibility

Status Terminated
Enrollment 36
Est. completion date September 2009
Est. primary completion date September 2009
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Both genders eligible for study.

- Female participants must use a contraceptive method.

- Tuberculin skin test between 1 and 15mm

- Participants must be able to understand and sign the Informed Consent, and comply with all aspects of the protocol.

- Subjects registered in a social security system or with health insurance cover

- First group: Healthy subjects aged from 18 to 75 years with 2 subgroups: 18-40 and 60-75 year old subjects

- Second group: Patients with kidney transplants of longer than 6 months on immunosuppressive treatment

Exclusion Criteria:

- Pregnant or lactating women.

- Previous allergic reaction to tuberculin skin test

- Active skin disease on testing zone

- Patients with a clinically significant disease (chronic, recurrent or active)

- Local or systemic medication which interacts with the outcome measures.

- Patients deprived of their civic rights, in custody, or under the care of a tutorial, judiciary or administrative body.

- Patients relevant of a protection measure

- Patients in a critical medical situation

- Patients with a personal situation evaluated by the investigator as unable to give an optimal participation in the study, or where it could constitute a risk for the patient

- Linguistic barrier or psychological profile disabling the patient from signing the consent form

- Patient still in an exclusion period following participation in another clinical trial

- Patients having earned more than 4500€ in indemnities following participation in clinical trials during the last 12 months, including this study

For group 1 only:

- Systemic corticotherapy or immunosuppressive treatment within the 2 weeks before first visit or within 2 weeks before the third visit or the biopsies.

- Systemic non anti-inflammatory drugs the week before the first visit or within 1 week before the third visit or the biopsies

Study Design

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science


Related Conditions & MeSH terms


Intervention

Biological:
Tuberculin antigen
2 intradermal injection of 50µl of antigen + 2 intradermal injection of 50µl of physiological serum

Locations

Country Name City State
France Centre Hospitalier Lyon Sud Pierre-benite

Sponsors (1)

Lead Sponsor Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cellular changes of recruited cells by immunochemical and histological analysis in the three groups of subjects (healthy young subjects, healthy old subjects and immunosuppressed patients) 30 minutes, 4 hours or 72 hours No
Secondary Molecular analysis of cytokines and chemokines involved in recruitment and/or function of immunocompetent cells 30 minutes, 4 hours or 72 hours No
Secondary Comparison of changes in the cutaneous immune system between the three groups of subjects 30 minutes, 4 hours or 72 hours No
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1